The impact of the restatement and other corrections on the condensed Consolidated Balance Sheet, Consolidated Statement of Operations and Consolidated Statement of Cash Flows as of and for the three and nine month periods ended September 30, 2015 and September 30, 2014 is presented below, in thousands except share and per share data.

Three Months Ended September 30, 2015

	As Previously			Restatement			Other
Consolidated Statement of Operations (unaudited)	Reported			Adjustments			Corrections		As Restated
Royalty revenue	$	—		$	776		$		$	776
Total revenue	38,586			776					39,362
Operating income	4,309			776					5,085
Interest expense — non-recourse liability related to sale of future royalties	—			(998		)			(998		)
Total other expense	(29		)	(998		)			(1,027		)
Earnings before income taxes	4,280			(222		)			4,058
Income tax expense	58						84		142
Net income	4,222			(222		)	(84	)	3,916
Income per common share: Basic	0.09			(0.01		)			0.08

Nine Months Ended September 30, 2015

	As Previously			Restatement			Other
Consolidated Statement of Operations (unaudited)	Reported			Adjustments			Corrections		As Restated
Royalty revenue	$	—		$	2,007		$		$	2,007
Total revenue	101,771			2,007					103,778
Selling, general and administrative	65,637						(141	)	65,496
Total costs and expenses	90,955						(141	)	90,814
Operating income	10,816			2,007			141		12,964
Interest expense — non-recourse liability related to sale of future royalties	—			(2,530		)			(2,530		)
Total other expense	(2,889		)	(2,530		)			(5,419		)
Earnings before income taxes	7,927			(523		)	141		7,545
Income tax expense	782						(329	)	453
Net income	7,145			(523		)	470		7,092

Nine Months Ended September 30, 2015

	As Previously			Restatement	Other
Consolidated Statements of Cash Flows (unaudited)	Reported			Adjustments	Corrections			As Restated
Net cash provided by operating activities	$	12,189			$	2,408		$	14,597
Net cash used in investing activities	(23,358		)		(3,061		)	(26,419		)
Net change in cash and cash equivalents	(10,102		)		(653		)	(10,755		)

As of September 30, 2015

	As Previously			Restatement		Other
Consolidated Balance Sheet (unaudited)	Reported			Adjustments		Corrections			As Restated
Cash and cash equivalents	$	26,294				$	(653	)	$	25,641
Marketable securities	31,408					653			32,061
Accrued expenses	21,353					301			21,654
Non-recourse liability related to sale of future royalties — current portion	—			261					261
Total current liabilities	43,128			261		301			43,690
Non-recourse liability related to sale of future royalties — long term	—			30,287					30,287
Total liabilities	57,205			30,548		301			88,054
Accumulated deficit	(151,512		)	(30,548	)	(301		)	(182,361		)
Total stockholders’ equity	109,436			(30,548	)	(301		)	78,587

As of December 31, 2014

	As Previously		Restatement		Other
Consolidated Balance Sheet	Reported		Adjustments		Corrections		As Restated
Accrued expenses	17,026				630		17,656
Total current liabilities	27,493				630		28,123
Non-recourse liability related to sale of future royalties — long term	—		30,025				30,025
Total liabilities	65,430		30,025		630		96,085
Additional paid-in capital	230,122				141		230,263
Accumulated deficit	(158,657	)	(30,025	)	(771	)	(189,453	)
Total stockholders’ equity	71,354		(30,025	)	(630	)	40,699

Three Months Ended September 30, 2014

	As Previously			Restatement			Other
Consolidated Statement of Operations (unaudited)	Reported			Adjustments			Corrections		As Restated
Royalty revenue	$	—		$	199		$		$	199
Revenue from royalty agreement	30,000			(30,000		)			—
Total revenue	52,488			(29,801		)			22,687
Selling, general and administrative	17,343						102		17,445
Total costs and expenses	23,321						102		23,423
Operating income (loss)	29,167			(29,801		)	(102	)	(736		)
Interest expense — non-recourse liability related to sale of future royalties	—			(326		)			(326		)
Total other expense	(1,309		)	(326		)			(1,635		)
Earnings before income taxes	27,858			(30,127		)	(102	)	(2,371		)
Net Income (loss)	27,858			(30,127		)	(102	)	(2,371		)
Income (loss) per common share: Basic	0.65			(0.71		)			(0.06		)
Income (loss) per common share: Diluted	0.39			(0.45		)			(0.06		)
Weighted average number of common shares - Diluted	50,825,633			(7,925,364		)			42,900,269

Nine Months Ended September 30, 2014

	As Previously			Restatement			Other
Consolidated Statement of Operations (unaudited)	Reported			Adjustments			Corrections		As Restated
Royalty revenue	$	—		$	199		$		$	199
Revenue from royalty agreement	30,000			(30,000		)			—
Total revenue	91,244			(29,801		)			61,443
Selling, general and administrative	54,452						102		54,554
Total costs and expenses	71,744						102		71,846
Operating Income (loss)	19,500			(29,801		)	(102	)	(10,403		)
Interest expense — non-recourse liability related to sale of future royalties	—			(326		)			(326		)
Total other expense	(3,984		)	(326		)			(4,310		)
Earnings before income taxes	15,516			(30,127		)	(102	)	(14,713		)
Net income (loss)	15,516			(30,127		)	(102	)	(14,713		)
Income (loss) per common share: Basic	0.37			(0.72		)			(0.35		)
Income (loss) per common share: Diluted	0.13			(0.48		)			(0.35		)
Weighted average number of common shares - Diluted	50,378,186			(8,343,161		)			42,035,025

Nine Months Ended September 30, 2014

	As Previously		Restatement		Other
Consolidated Statements of Cash Flows (unaudited)	Reported		Adjustments		Corrections			As Restated
Net cash provided by (used in) operating activities	$	739	(30,000	)	$	(1,497	)	$	(30,758	)
Net cash provided by investing activities	3,797				1,497			5,294
Net cash provided by financing activities	264		30,000					30,264

As of September 30, 2014

	As Previously		Restatement		Other
Consolidated Balance Sheet (unaudited)	Reported		Adjustments		Corrections		As Restated
Non-recourse liability related to sale of future royalties — long term	—		30,127				30,127
Total liabilities	60,206		30,127		(765	)	89,568
Additional paid-in capital	229,123				102		229,225
Accumulated deficit	(163,012	)	(30,127	)	(102	)	(193,241	)
Total stockholders’ equity	66,119		(30,127	)			35,992